|
Journal of Histochemistry and Cytochemistry, Vol. 50, 885-890, July 2002, Copyright © 2002, The Histochemical Society, Inc.
Localization of Urotensin-II Immunoreactivity in Normal Human Kidneys and Renal Carcinoma
Andre Shenoudaa,
Stephen A. Douglasb,
Eliot H. Ohlsteinb, and
Adel Giaida
a The Montreal General Hospital, McGill University, Montreal, Quebec, Canada
b GlaxoSmithKline, King of Prussia, Pennsylvania
Correspondence to:
Adel Giaid, Montreal General Hospital, Suite L3-314, Montreal, Quebec H3G 1A4, Canada. E-mail: adel.giaid@mcgill.ca
Human urotensin-II (U-II) is a cyclic 11-amino-acid residue peptide with a wide range of vasoactive properties dependent on the anatomic site and the species studied. The purpose of this study was to determine the localization of human U-II in normal human kidneys and in renal carcinoma. Normal human kidneys (n=11) and eight cases of clear-cell carcinoma were immunostained with a polyclonal antibody to human U-II. In normal human kidneys, U-II was mostly present in the epithelial cells of tubules and ducts, with greater intensity in the distal convoluted tubules. Moderate U-II immunoreactivity was seen in the endothelial cells of renal capillaries, but only focal immunoreactivity was found in the endothelial cells of the glomeruli. No staining was found in the veins. All tumors expressed moderate U-II immunoreactivity in the cancer cells and vasculature. Here we demonstrate abundant expression of U-II in normal human kidneys and renal carcinoma. These findings suggest that the vasoactive and growth-mediator peptide U-II may contribute to the pathophysiology of the human renal system.
(J Histochem Cytochem 50:885889, 2002)
Key Words:
epithelial cells, endothelial cells, clear cells, tubules

CiteULike Complore Connotea Del.icio.us Digg Reddit Technorati What's this?
This article has been cited by other articles:

|
 |

|
 |
 
L. Tian, C. Li, J. Qi, P. Fu, X. Yu, X. Li, and L. Cai
Diabetes-induced upregulation of urotensin II and its receptor plays an important role in TGF-{beta}1-mediated renal fibrosis and dysfunction
Am J Physiol Endocrinol Metab,
November 1, 2008;
295(5):
E1234 - E1242.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
C. Zoccali, F. Mallamaci, F. A. Benedetto, G. Tripepi, P. Pizzini, S. Cutrupi, and L. Malatino
Urotensin II and Cardiomyopathy in End-Stage Renal Disease
Hypertension,
February 1, 2008;
51(2):
326 - 333.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
A. Mosenkis, T. M. Danoff, N. Aiyar, J. Bazeley, and R. R. Townsend
Human Urotensin II in the plasma of anephric subjects
Nephrol. Dial. Transplant.,
April 1, 2007;
22(4):
1269 - 1270.
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
Y.-X. Wang, Y.-J. Ding, Y.-Z. Zhu, Y. Shi, T. Yao, and Y.-C. Zhu
Role of PKC in the novel synergistic action of urotensin II and angiotensin II and in urotensin II-induced vasoconstriction
Am J Physiol Heart Circ Physiol,
January 1, 2007;
292(1):
H348 - H359.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
W. Lu, M. Greenwood, L. Dow, J. Yuill, J. Worthington, M. J. Brierley, C. R. McCrohan, D. Riccardi, and R. J. Balment
Molecular Characterization and Expression of Urotensin II and its Receptor in the Flounder (Platichthys flesus): A Hormone System Supporting Body Fluid Homeostasis in Euryhaline Fish
Endocrinology,
August 1, 2006;
147(8):
3692 - 3708.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
E. Ovcharenko, Z. Abassi, I. Rubinstein, A. Kaballa, A. Hoffman, and J. Winaver
Renal effects of human urotensin-II in rats with experimental congestive heart failure
Nephrol. Dial. Transplant.,
May 1, 2006;
21(5):
1205 - 1211.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
M. Clozel, P. Hess, C. Qiu, S.-S. Ding, and M. Rey
The Urotensin-II Receptor Antagonist Palosuran Improves Pancreatic and Renal Function in Diabetic Rats
J. Pharmacol. Exp. Ther.,
March 1, 2006;
316(3):
1115 - 1121.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
G. Giebing, M. Tolle, J. Jurgensen, J. Eichhorst, J. Furkert, M. Beyermann, F. Neuschafer-Rube, W. Rosenthal, W. Zidek, M. van der Giet, et al.
Arrestin-Independent Internalization and Recycling of the Urotensin Receptor Contribute to Long-Lasting Urotensin II-Mediated Vasoconstriction
Circ. Res.,
September 30, 2005;
97(7):
707 - 715.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
M. Clozel, C. Binkert, M. Birker-Robaczewska, C. Boukhadra, S.-S. Ding, W. Fischli, P. Hess, B. Mathys, K. Morrison, C. Muller, et al.
Pharmacology of the Urotensin-II Receptor Antagonist Palosuran (ACT-058362; 1-[2-(4-Benzyl-4-hydroxy-piperidin-1-yl)-ethyl]-3-(2-methyl-quinolin-4-yl)-urea Sulfate Salt): First Demonstration of a Pathophysiological Role of the Urotensin System
J. Pharmacol. Exp. Ther.,
October 1, 2004;
311(1):
204 - 212.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
D. Onan, L. Pipolo, E. Yang, R. D. Hannan, and W. G. Thomas
Urotensin II Promotes Hypertrophy of Cardiac Myocytes via Mitogen-Activated Protein Kinases
Mol. Endocrinol.,
September 1, 2004;
18(9):
2344 - 2354.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
A. Y. Zhang, Y.-F. Chen, D. X. Zhang, F.-X. Yi, J. Qi, P. Andrade-Gordon, L. de Garavilla, P.-L. Li, and A.-P. Zou
Urotensin II is a nitric oxide-dependent vasodilator and natriuretic peptide in the rat kidney
Am J Physiol Renal Physiol,
October 1, 2003;
285(4):
F792 - F798.
[Abstract]
[Full Text]
[PDF]
|
 |
|
The Journal of Histochemistry & Cytochemistry
is owned, published, and licensed by
The Histochemical Society © 2002
|
|
|